RINVOQ (Abbvie Pty Ltd)
Product name
RINVOQ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
197 (255 working days)
Active ingredients
upadacitinib hemihydrate
Registration type
EOI
Indication
Atopic Dermatitis
RINVOQ 30 mg and 15 mg (modified release tablet blister pack) is now also indicted for use in adults and adolescents aged 12 years and above who weigh at least 40 kg, for the treatment of moderate to severe atopic dermatitis which is inadequately controlled with active topical pharmacotherapies and for whom systemic therapy is indicated.